35% to 43% of mCRC [3] [4] [5] [6] . Results from clinical trials showed that patients with the normal (wild-type) KRAS gene responded to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies, cetuximab (Erbitux ® ) and panitumumab (Vectibix ® ); whereas those with the KRAS mutation did not [6] [7] [8] . Furthermore, these monoclonal antibody therapies have demonstrated improved progression-free survival and overall survival in patients with wild-type KRAS tumors [9, 10] . As a result, the National Comprehensive Cancer Network (NCCN) updated its CRC guidelines in 2008 to recommend KRAS testing for all mCRC patients upon diagnosis and prior to treatment [11] . In April 2009, the American Society of Clinical Oncology (ASCO) released a guideline recommendation to test for KRAS in mCRC patients who were candidates for anti-EGFR treatment [12] . Consequently, the US Food and Drug Administration (FDA) implemented labeling changes in July 2009 to cetuximab (originally approved in 2004) and panitumumab (originally approved in 2006) after clinical trials revealed the benefit of these agents for those with a wild-type KRAS oncogene [13] . At the time of data collection for mCRC diagnosis year 2011, NCCN guidelines recommended testing for the KRAS oncogene only among mCRC patients [14] . However, the evolution of recent research found that mCRC patients with RAS mutations on the KRAS as well as the NRAS oncogene do not respond to anti-EGFR treatment either [15] [16] [17] . NCCN currently recommends genotyping tumor tissue for both KRAS and NRAS mutations for mCRC giving a result of either normal (wild-type) and able to receive anti-EGFR treatment; or a mutated status and should not be treated with anti-EGFR treatment [18] . NCCN recommends genotyping the tumor tissue to test for these oncogenes; however, a particular method (e.g., sequencing, hybridization) is not recommended [18] .
The primary objective of this study was to determine KRAS testing in clinical practice for mCRC diagnosis year 2011 in ten US states using data from the Centers for Disease Control and Prevention's (CDC) population-based central cancer registries as well as evaluate the association of patient demographics and socioeconomic measures with the use of KRAS testing. This study also examines treatment received within 12 months of diagnosis of mCRC, with attention to anti-EGFR treatment by KRAS testing status and results.
Materials and methods

Data source
Funding from the American Recovery and Reinvestment Act of 2009 allowed CDC's National Program of Cancer Registries (NPCR) to enhance standard practices and collect additional biomarker and treatment data in ten central cancer registries (Alaska, California, Colorado, Florida, Idaho, Louisiana, New Hampshire, North Carolina, Rhode Island, and Texas) to support Comparative Effectiveness Research (CER) [19] . Participating central cancer registries collected data on all patients who were diagnosed with CRC in 2011 in their entire state with the exception of California and Florida, whose catchment areas were 13 counties in the Sacramento area and 5 Miami metro counties, respectively. At the time of data collection for diagnosis year 2011, the NCCN guidelines recommended testing for the KRAS oncogene only [14] . Certified Tumor Registrars abstracted both NPCR required standard variables from the North American Association of Central Cancer Registries (NAACCR) and defined non-NAACCR standard data items and included information up to 12 months post-diagnosis [19] .
Information regarding KRAS biomarker testing and firstline chemotherapy agents was collected for the first time in NPCR as part of this project. Abstractors collected KRAS testing and treatment information by several means including onsite visits to diagnosis/treatment facilities, remote access to patients' medical records, or by facilities sending the information to the registries [19] . Receiving a KRAS test, defined as "Tested" meant there was documentation in a patient's medical record; otherwise, if no documentation was found then we assumed no KRAS testing was performed and defined as "Not Tested." To standardize collection of treatment agents, abstractors collected the Cancer Chemotherapy National Service Center (NSC) number assigned to oncology drugs provided by the National Cancer Institute (NCI) SEERRx -Interactive Antineoplastic Drugs Database [20] , or if a number did not exist in the database CDC assigned the drug a specific number. During the creation of the analytic data set, project staff converted NSC numbers to generic agent names using information provided by NCI's SEERRx -Interactive Antineoplastic Drugs Database and SAS programs. A detailed description of the CER project and study methodology has been published [19] . Currently, NPCR does not collect KRAS or NRAS biomarker testing data; the collection of KRAS biomarker data was a special project from cancer diagnosis year 2011 only.
Study population
This study included 4,626 male and female patients residing in ten CDC central cancer registries who were diagnosed with mCRC (ICD-O-3 site codes: C18.0, C18.2 -C18.9, C19.9, and C20.9) in 2011. We excluded cases with histologies that did not meet the American Joint Committee on Cancer (AJCC) 7 th edition staging for CRCs (n = 93), missing KRAS testing information (n = 6), unknown/other race (n = 147), transsexual/unknown sex (n = 3), and patients who died within two months of diagnosis or had missing information on the time from diagnosis to death (n = 769). These patients were excluded because if they were too sick to be treated then more than likely they would not be tested for KRAS. A total of 3,608 (78%) mCRC cases met criteria and were included in the data analysis ( Figure 1 ).
Data variables
Demographic variables evaluated were age at diagnosis, race/ethnicity, sex, residence at diagnosis, and insurance status. Census tract-level socioeconomic variables assessed were poverty level, education, and rural/urban residence, which were linked to the data set from the 2010 US Census Bureau American Community Survey (ACS) [21] . Poverty level was dichotomized into two categories: living in a census tract with < 20% or ≥ 20% of people living under federal poverty level. Education level was also dichotomized into two categories: low and high education Time to death within two months or missing (n=769), unknown race or sex (n = 150), histology that did not meet criteria for staging (n=93), missing KRAS testing information (n=6).
level. Low education level was defined as living in a census tract with ≥ 25% adults (age 25 years and older) without a high school education, and high education level was defined as living in a census tract with < 25% without a high school education. Rural/urban residence was defined as urban, rural, or mixed by census tract. A comorbid condition was defined as a pre-existing health condition and/or a health condition diagnosed during the cancer treatment. Quan's coding algorithms were used to define comorbid conditions in ICD-9-CM [22] . We included up to 15 comorbidities in this study, and they were categorized based on the number of Charlson comorbidities (none, 1, 2 or more) [23] . Comorbidities were considered not present if no comorbidity was documented in the medical chart or if it was unknown whether a patient had Charlson comorbidity when the cancer was diagnosed. Treatment regimens were then defined according to 2011 NCCN guidelines [14] . Receiving anti-EGFR treatment was defined as receiving cetuximab or panitumumab, either in combination with a regimen or alone.
Statistical methods
We examined the association of demographics, socioeconomic measures, and comorbidities using the Pearson Chi-square test for discrete variables and the Kruskal-Wallis test for continuous variables; differences were considered significant at P < 0.05. Some variables had missing information: insurance status (n = 161), census tract poverty (n = 21), census tract education (n = 17), and census tract rural/urban (n = 17). A multivariate logistic regression model was used to determine the significant predictors of KRAS testing (Tested vs. Not Tested). Independent variables were age at diagnosis, race/ethnicity, sex, residence at diagnosis, insurance status, comorbidities, and census tract-level poverty, education, and rural/urban residence. The linearity assumption for the continuous age variable was assessed using restricted cubic spline functions [24] . The plot of the restricted cubic spline fit suggested a piecewise linear relationship between age at diagnosis and KRAS testing. In the final model, age at diagnosis is transformed using a linear spline function with a knot at age 70 because age was split into two linear segments at age 70.
Results
KRAS testing
Of the 3,608 mCRC cases, 992 (27%) received a documented KRAS test compared to 2,616 (73%) with no documented KRAS test (Table 1) . Of the 992 cases with a documented KRAS test, 534 (54%) had a normal KRAS gene, 422 (42%) had a mutated gene, and 36 (4%) had a test ordered but results were not available in the chart (Figure 1 ).
Among the patient characteristics (Table 1) , older age at diagnosis, race/ethnicity other than White, public insurance, and lower census tract education were all associated with less KRAS testing. Cases who did not receive a KRAS test had a median age of 64 years ((25 th , 75 th percentile) 55, 75) compared to a median age of 61 years (51, 69) for those who did receive a KRAS test. Among the age categories analyzed, those who were ≥ 75 had the lowest use of KRAS testing (18%) compared with the other age groups. Hispanics and non-Hispanic Blacks had the lowest use of KRAS testing (25% and 24% respectively) compared to nonHispanic Whites (29%). Those with Medicaid or Medicare and other public insurance had lower use of KRAS testing (26% and 25%, respectively) compared to those with no insurance and private insurance (both 31%). Living in a census tract with low education level was associated with lower use of KRAS testing (24%). There were also significant differences in KRAS testing by residence at diagnosis (p < 0.0001). The lowest rates were in California (18%), Louisiana (23%), Texas (23%), and Florida (26%) among the ten central cancer registries. There were no statistically significant differences in KRAS testing by sex, census tract poverty, census tract rural/urban, and comorbidities.
In multivariate analysis (Table 2) , after adjusting for all covariates age at diagnosis, and residence at diagnosis remained significant predictors of KRAS testing (both p < 0.0001). The relationship between age and KRAS testing was non-linear. Increased age was associated with lower KRAS testing, but this effect was stronger above age 70 (OR = 0.76, 95% CI = 0.69-0.84 vs. OR = 0.92, 95% CI = 0.88 -0.96 below age 70 per 5-year increase). The model confirmed geographic differences in KRAS testing (p < 0.0001). Colorado, Idaho, New Hampshire, Rhode Island, and North Carolina had more KRAS testing compared to Texas (referent group). Texas was used as the referent group because they had the largest number of cases. Among these states, the odds of receiving a KRAS test was highest for New Hampshire and Rhode Island (almost 3 times higher). The overall effect of race/ethnicity across all age groups was not statistically significant. However, the effect of non-Hispanic Blacks compared to non-Hispanic Whites was statistically significant; non-Hispanic Blacks had lower KRAS testing compared to non-Hispanic Whites (OR = 0.77, 95% CI = 0.61-0.97).
First-line treatment
Of the 992 cases who had documented KRAS testing, detailed first treatment information was recorded for 678 cases (after excluding 110 cases who reported no chemotherapy; 34 whose chemotherapy status was unknown; 4 cases with discrepancies among treatment variables; and 166 lacking detailed chemotherapy) ( Table 3) . The most common regimens were FOLFOX + bevacizumab (30%) and FOLFOX alone (17%), which are both first-line NCCN-recommended treatments at the time [14] . Twenty four cases with a document KRAS test (3%) received anti-EGFR treatment ( Note: a There were 179 missing values excluded from the logistic regression; b Age was transformed in the model using a linear spline function with a knot at Age = 70. The p-value for age is based on the test statistic from the simultaneous test that both age coefficients are equal to 0;
c From selected catchment areas. had no documentation of KRAS testing (Table 3) . These cases received similar first-line treatment trend as those who were tested for KRAS. The most common treatments received were FOLFOX + bevacizumab (28%) or FOLFOX alone (17%) ( Table 3) . Thirteen cases (1%) received anti-EGFR treatment even though these cases did not have a documented KRAS test (Table 3) . [25, 26] . Also, 2009 KRAS testing guidance from ASCO was more conservative, encouraging testing if anti-EGFR treatment was considered rather than for all patients. Our findings support that clinicians are using FOLFOX + bevacizumab or FOLFOX alone as mCRC first-line treatment, options which do not require a KRAS test.
Disparities in testing and treatment decisions by age, race, or geography may also be a factor influencing the receipt of a KRAS test. First, we observed older patients were less likely to have a documented KRAS test and this was more significant for patients who were 70 years and older. This is probably influenced by older patients having poorer health, more comorbidities, and/or their refusal to therapy or a physician's choice to use another type of treatment [27] [28] [29] [30] . Second, in contrast to previous studies, we found a racial disparity in receiving a KRAS test among mCRC cancer patients [31, 32] . Our findings indicate that the odds of receiving a KRAS test are 23% lower for nonHispanic Blacks than for non-Hispanic Whites. Wallace et al. demonstrated that Blacks were less likely than Whites to receive a physician's recommendation for CRC screening [31] . Blacks are also more likely to have advanced CRC but less likely to be informed about CRC guidelines when compared to Whites [32] . Blacks are overall less likely to be treated with chemotherapy and since KRAS testing is closely tied to treatment, it is possible they are receiving less KRAS testing because of this [32] . More significantly, our study is the first to collect detailed first-line treatment agents, including anti-EGFR, for mCRC on a population level by KRAS status. We found that anti-EGFR is given sparingly as first-line treatment including among those with a documented normal KRAS. However, no one in our study received anti-EGFR treatment who was tested and had a mutated gene. The low use of anti-EGFR treatment was also seen in Abrams et al. study, given to only 4% of their US-wide mCRC cohort [37] . Our data showed that FOLFOX + bevacizumab was the most common first-line chemotherapy treatment given to both tested and not tested groups. The second most common treatment was FOLFOX among both groups. Both of these treatments do not require a KRAS test. According to NCCN guidelines, there are several chemotherapy first-line regimens a physician can chose to prescribe a patient, other than anti-EGFR treatment, that are equally efficient based on NCCN recommendations and would not require a KRAS test. Moreover, another underlying factor potentially influencing physicians to use anti-EGFR treatment so sparingly is that it is substantially more expensive than other available treatments [7] ; however, cost was not evaluated in this study. 
Conclusion
This is the first population-based study that assessed both KRAS testing and detailed first-line treatment information. Our findings help understand KRAS testing in the diagnosis year 2011, which to our knowledge is the latest populationbased data on KRAS testing. The limited use of KRAS testing and use of anti-EGFR treatment reflects the slow adoption and incorporation of biomarkers in cancer care, despite guidance from professional organizations. The application of biomarkers is expanding in the diagnosis and treatment of solid tumors. Thus, there is a need to validate the capture of these factors in cancer surveillance systems as well as conduct longitudinal studies to examine testing and treatment beyond the first year of diagnosis, including the impact on cancer recurrence and death. The findings of our study, however, demonstrated that capacity of cancer registries to assess KRAS to document the uptake of KRAS testing in the United States and provide the foundation to study the impact of KRAS on treatment decisions and patient-centered outcomes.
